Hepcidin regulation in prostate and its disruption in prostate cancer

Cancer Research

Volumn 75, Issue 11, 2015, Pages 2254-2263

  Tesfay, Lia ^a   Clausen, Kathryn A ^b   Kim, Jin Woo ^c   Hegde, Poornima ^a   Wang, Xiaohong ^a   Miller, Lance D ^d   Deng, Zhiyong ^a   Blanchette, Nicole ^a   Arvedson, Tara ^e   Miranti, Cindy K ^f   Babitt, Jodie L ^g   Lin, Herbert Y ^g   Peehl, Donna M ^h   Torti, Frank M ^a   Torti, Suzy V ^a  

^a UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

^b JK   (United States)

^c Panagene Inc   (South Korea)

^d WAKE FOREST SCHOOL OF MEDICINE   (United States)

^e AMGEN INC   (United States)

^f VAN ANDEL RESEARCH INSTITUTE   (United States)

^g MASSACHUSETTS GENERAL HOSPITAL   (United States)

^h STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APC PROTEIN; AXIN; AZACITIDINE; BETA CATENIN; BONE MORPHOGENETIC PROTEIN 4; FERROPORTIN; GLYCOGEN SYNTHASE KINASE 3BETA; HEPCIDIN; INTERLEUKIN 6; LYMPHOID ENHANCER FACTOR 1; OSTEOGENIC PROTEIN 1; PROSTATE SPECIFIC ANTIGEN; SCLEROSTIN; SCLEROSTIN DOMAIN CONTAINING 1 PROTEIN; UNCLASSIFIED DRUG; WNT PROTEIN; IRON; PROTEIN; SOSTDC1 PROTEIN, HUMAN;

ARTICLE; AUTOCRINE EFFECT; CANCER GROWTH; CANCER RECURRENCE; CELL SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; CPG ISLAND; DEMETHYLATION; DNA METHYLATION; DOWN REGULATION; EPIGENETICS; FEMALE; GENE SILENCING; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IRON METABOLISM; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE CANCER CELL LINE; PROSTATE EPITHELIUM CELL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN SECRETION; PROTEIN SYNTHESIS; SIGNAL TRANSDUCTION; WESTERN BLOTTING; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; CANCER GRADING; DISEASE COURSE; EPITHELIUM CELL; GENETIC EPIGENESIS; GENETICS; MALE; METABOLISM; PATHOLOGY; PROSTATE; PROSTATE TUMOR; SECRETION (PROCESS); TUMOR CELL LINE;

CELL LINE, TUMOR; DISEASE PROGRESSION; EPIGENESIS, GENETIC; EPITHELIAL CELLS; HEPCIDINS; HUMANS; IRON; MALE; NEOPLASM GRADING; PROSTATE; PROSTATIC NEOPLASMS; PROTEINS; SIGNAL TRANSDUCTION;

EID: 84942888188     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-14-2465     Document Type: Article

References (44)

1. Ganz T, Nemeth E. Hepcidin and iron homeostasis. Biochim Biophys Acta 2012;1823:1434-43.
2. Nemeth E, Tuttle MS, Powelson J, Vaughn MB, Donovan A, Ward DM, et al. Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science 2004;306:2090-3.
3. Ganz T, Nemeth E. Iron sequestration and anemia of inflammation. Semin Hematol 2009;46:387-93.
4. Andriopoulos B Jr, Corradini E, Xia Y, Faasse SA, Chen S, Grgurevic L, et al. BMP6 is a key endogenous regulator of hepcidin expression and iron metabolism. Nat Genet 2009;41:482-7.
5. Sun CC, Vaja V, Babitt JL, Lin HY. Targeting the hepcidin-ferroportin axis to develop new treatment strategies for anemia of chronic disease and anemia of inflammation. Am J Hematol 2012;87:392-400.
6. Pietrangelo A, Dierssen U, Valli L, Garuti C, Rump A, Corradini E, et al. STAT3 is required for IL-6-gp130-dependent activation of hepcidin in vivo. Gastroenterology 2007;132:294-300.
7. Pinnix ZK, Miller LD, Wang W, D'Agostino R Jr, Kute T, Willingham MC, et al. Ferroportin and iron regulation in breast cancer progression and prognosis. Sci Transl Med 2010;2:43ra56.
8. Schwarz P, Kubler JA, Strnad P, Muller K, Barth TF, Gerloff A, et al. Hepcidin is localised in gastric parietal cells, regulates acid secretion and is induced by Helicobacter pylori infection. Gut 2012;61:193-201.
9. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin 2014;64:9-29.
10. Karantanos T, Corn PG, Thompson TC. Prostate cancer progression after androgen deprivation therapy: mechanisms of castrate resistance and novel therapeutic approaches. Oncogene 2013;32:5501-11.
11. Lamb LE, Knudsen BS, Miranti CK. E-cadherin-mediated survival of androgen- receptor-expressing secretory prostate epithelial cells derived from a stratified in vitro differentiation model. J Cell Sci 2010;123:266-76.
12. Wang W, Di X, D'Agostino RB Jr, Torti SV, Torti FM. Excess capacity of the iron regulatory protein system. J Biol Chem 2007;282:24650-9.
13. Kim JW, Cheng Y, Liu W, Li T, Yegnasubramanian S, Zheng SL, et al. Genetic and epigenetic inactivation of LPL gene in human prostate cancer. Int J Cancer 2009;124:734-8.
14. Kobayashi Y, Absher DM, Gulzar ZG, Young SR, McKenney JK, Peehl DM, et al. DNA methylation profiling reveals novel biomarkers and important roles for DNA methyltransferases in prostate cancer. Genome Res 2011;21:1017-27.
15. Kim JW, Kim ST, Turner AR, Young T, Smith S, Liu W, et al. Identification of new differentially methylated genes that have potential functional consequences in prostate cancer. PLoS ONE 2012;7:e48455.
16. Du P, Zhang X, Huang CC, Jafari N, Kibbe WA, Hou L, et al. Comparison of Beta-value and M-value methods for quantifying methylation levels by microarray analysis. BMC Bioinformatics 2010;11:587.
17. Babitt JL, Huang FW, Wrighting DM, Xia Y, Sidis Y, Samad TA, et al. Bone morphogenetic protein signaling by hemojuvelin regulates hepcidin expression. Nat Genet 2006;38:531-9.
18. Blish KR, Wang W, Willingham MC, Du W, Birse CE, Krishnan SR, et al. A human bonemorphogenetic protein antagonist is down-regulated in renal cancer. Mol Biol Cell 2008;19:457-64.
19. Taylor BS, Schultz N, Hieronymus H, Gopalan A, Xiao Y, Carver BS, et al. Integrative genomic profiling of human prostate cancer. Cancer Cell 2010; 18:11-22.
20. Culig Z, Puhr M. Interleukin-6: a multifunctional targetable cytokine in human prostate cancer. Mol Cell Endocrinol 2012;360:52-8.
21. Walsh DW, Godson C, Brazil DP, Martin F. Extracellular BMP-antagonist regulation in development and disease: tied up in knots. Trends Cell Biol 2010;20:244-56.
22. Yanagita M, OkaM, Watabe T, Iguchi H, Niida A, Takahashi S, et al. USAG- 1: a bone morphogenetic protein antagonist abundantly expressed in the kidney. Biochem Biophys Res Commun 2004;316:490-500.
23. Tanaka M, Endo S, Okuda T, Economides AN, Valenzuela DM, Murphy AJ, et al. Expression of BMP-7 and USAG-1 (a BMP antagonist) in kidney development and injury. Kidney Int 2008;73:181-91.
24. Clausen KA, Blish KR, Birse CE, Triplette MA, Kute TE, Russell GB, et al. SOSTDC1 differentially modulates Smad and beta-catenin activation and is down-regulated in breast cancer. Breast Cancer Res Treat 2011;129: 737-46.
25. Gopal G, Raja UM, Shirley S, Rajalekshmi KR, Rajkumar T. SOSTDC1 down-regulation of expression involves CpG methylation and is a potential prognostic marker in gastric cancer. Cancer Genet 2013;206:174-82.
26. Rajkumar T, Vijayalakshmi N, Gopal G, Sabitha K, Shirley S, Raja UM, et al. Identification and validation of genes involved in gastric tumorigenesis. Cancer Cell Int 2010;10:45.
27. Li X, Zhang Y, Kang H, Liu W, Liu P, Zhang J, et al. Sclerostin binds to LRP5/6 and antagonizes canonical Wnt signaling. J Biol Chem 2005;280: 19883-7.
28. Clevers H, Nusse R. Wnt/beta-catenin signaling and disease. Cell 2012; 149:1192-205.
29. Chen B, Dodge ME, Tang W, Lu J, Ma Z, Fan CW, et al. Small moleculemediated disruption of Wnt-dependent signaling in tissue regeneration and cancer. Nat Chem Biol 2009;5:100-7.
30. Timp W, Feinberg AP. Cancer as a dysregulated epigenome allowing cellular growth advantage at the expense of the host. Nat Rev Cancer 2013; 13:497-510.
31. Bentley H, Hamdy FC, Hart KA, Seid JM, Williams JL, Johnstone D, et al. Expression of bone morphogenetic proteins in human prostatic adenocarcinomaand benign prostatic hyperplasia. Br J Cancer 1992;66:1159-63.
32. Ye L, Lewis-Russell JM, Kyanaston HG, Jiang WG. Bone morphogenetic proteins and their receptor signaling in prostate cancer. HistolHistopathol 2007;22:1129-47.
33. Yuen HF, Chan YP, Cheung WL, Wong YC, Wang X, Chan KW. The prognostic significance of BMP-6 signaling in prostate cancer. Mod Pathol 2008;21:1436-43.
34. Masuda H, Fukabori Y, Nakano K, Takezawa Y, T CS, Yamanaka H. Increased expression of bone morphogenetic protein-7 in bone metastatic prostate cancer. Prostate 2003;54:268-74.
35. Mimeault M, Batra SK. Recent advances on multiple tumorigenic cascades involved in prostatic cancer progression and targeting therapies. Carcinogenesis 2006;27:1-22.
36. Sakai I, Miyake H, Terakawa T, Fujisawa M. Inhibition of tumor growth and sensitization to chemotherapy by RNA interference targeting interleukin-6 in the androgen-independent human prostate cancer PC3 model. Cancer Sci 2011;102:769-75.
37. Rojas A, Liu G, Coleman I, Nelson PS, Zhang M, Dash R, et al. IL-6 promotes prostate tumorigenesis and progression through autocrine cross-activation of IGF-IR. Oncogene 2011;30:2345-55.
38. Dorff TB, Goldman B, Pinski JK, Mack PC, Lara PN Jr, Van Veldhuizen PJ Jr, et al. Clinical and correlative results of SWOG S0354: a phase II trial of CNTO328 (siltuximab), a monoclonal antibody against interleukin-6, in chemotherapy-pretreated patients with castration-resistant prostate cancer. Clin Cancer Res 2010;16:3028-34.
39. Tanno T, Rabel A, Alleyne M, Lee YT, Dahut WL, Gulley JL, et al. Hepcidin, anaemia, and prostate cancer. BJU Int 2011;107:678-9.
40. Rider CC, Mulloy B. Bone morphogenetic protein and growth differentiation factor cytokine families and their protein antagonists. Biochem J 2010;429:1-12.
41. Torti SV, Torti FM. Iron and cancer: more ore to be mined. Nat Rev Cancer 2013;13:342-55.
42. Clark RJ, Preza GC, Tan CC, van Dijk JW, Fung E, Nemeth E, et al. Design, synthesis, and characterization of cyclic analogues of the iron regulatory peptide hormone hepcidin. Biopolymers 2013;100:519-26.
43. Fung E, Sugianto P, Hsu J, Damoiseaux R, Ganz T, Nemeth E. Highthroughput screening of small molecules identifies hepcidin antagonists. Mol Pharmacol 2013;83:681-90.
44. Casanovas G, Mleczko-Sanecka K, Altamura S, Hentze MW, Muckenthaler MU. Bone morphogenetic protein (BMP)-responsive elements located in the proximal and distal hepcidin promoter are critical for its response to HJV/BMP/SMAD. J Mol Med 2009;87:471-80.